



CITY OF NEW YORK
MANHATTAN COMMUNITY BOARD FOUR

tel: 212-736-4536
www.nyc.gov/mcb4

JESSICA CHAIT
Chair

JESSE R. BODINE
District Manager

November 17, 2025

NYS Senator Gustavo Rivera
Chair, Committee on Health
Albany Office
172 State Street, Capitol Building 502C
Albany, NY 12247

NYS Senator Liz Krueger
Chair, Finance Committee
Albany Office
172 State Street, Capitol Building Room 416 CAP
Albany, NY 12247

NYS Assemblymember Amy Paulin
Chair, Committee on Health
Albany Office
LOB 822
Albany, NY 12248

**Re: 340B Prescription Drug Anti-Discrimination Act
Senate Bill S1913 and Assembly Bill A6222**

Dear Senator Rivera, Senator Krueger, and Assemblymember Paulin,

At its November 5, 2025 Full Board meeting, by a vote of 43 in favor, 0 opposed, 0 abstaining, and 1 present but not eligible to vote¹, Manhattan Community Board 4 (MCB4) expresses support to establish the “340 B prescription drug anti-discrimination act” for Senate Bill S1913 and Assembly Bill A6222. We encourage you and your colleagues to advance and expedite passage of these Bills.

This action follows the unanimous support of MCB4’s Housing, Health, and Human Services (HHHS) Committee at its meeting on October 7, 2025. At the meeting, the Committee received a presentation from the Ryan Chelsea-Clinton (RCC) Community Health Center leadership, Executive Director Sarina Jean-Louis and Deputy Director William Arboleda.

¹ Maria Ortiz is a member of MCB4 and Co-Chair of the Housing, Health & Human Services Committee. Ms. Ortiz recused herself from voting at the committee meeting & CB4 Full Board meeting.

MCB4 supports passage of Senate Bill S1913 and Assembly Bill A6222 to protect and preserve the ability of safety-net facilities such as RCC and others throughout New York State to have the desperately needed funds to provide and expand services. These services especially serve vulnerable and underserved patient populations to have access to lower outpatient drug costs and vital health care services.

Ryan Chelsea-Clinton's Critical Role in Providing Vital Health Services to the Underserved and Vulnerable Patient Population

In 1967, Ryan Health was established to meet the community's need for healthcare services on the Upper West Side of Manhattan. In 1977, it became an independent, community-controlled health center, and in 1978, was renamed in memory of its greatest advocate, U. S. Congressman William F. Ryan.

Today, Ryan Health is a Network of health centers across Manhattan providing access to a wide range of high quality, affordable, health care services for over 50,000 patients. Ryan Health is committed to maintaining its role as a leader in the Community Health Center movement. As a team of dedicated individuals, staff are responsive to the needs of the community and continually strive to enhance and improve services to ensure the highest quality of care. Ryan Health is dedicated to providing high quality, affordable, comprehensive, linguistically appropriate and culturally competent health care services to medically underserved populations. All patients are treated equally with dignity, respect, courtesy, confidentiality, and concern for safety.

RCC is located at 645 10th Ave (between W45th and W46th Streets) in Manhattan. RCC was founded in 2001 as an independent affiliate of Ryan Health to meet the needs of the Chelsea, Clinton, and Hell's Kitchen neighborhoods and currently has over 13,000 registered patients.

RCC serves all patients regardless of the ability to pay, and accepts Medicaid, Medicaid Managed Care Plans Medicare, and most private insurances. For patients who are uninsured or underinsured, it offers a sliding fee scale based on family size and income as well as a low-cost pharmacy plan.

Financial Challenges Facing Ryan Chelsea-Clinton Today

The fiscal challenges of RCC are unfortunately similar to other safety-net facilities and community health centers. Community Health Centers are dealing with many Budget Cuts including:

- CHCs are already in a precarious position given the Medicaid and ACA cuts included in the budget reconciliation bill.
- The uninsured population is expected to soar from its current 5% to over 20%.
- The Governor announced that approximately 730,000 New Yorkers will lose their Essential Plan coverage in 2026²—approximately 500 would do so at RCC.
- Ryan Chelsea-Clinton remains seriously concerned about restrictions on the HRSA funds that are intended to support general operations and primary care. These restrictions place RCC at risk of losing essential funding simply for providing gender affirming care.
- RCC temporarily lost AmeriCorps support due to an abrupt funding cut by the Administration. While funding has resumed, its future remains uncertain.

² [New York State of Health, Understanding the Impact of the Federal Reconciliation Bill on New York](#)

The 340B Program

The 340B Program, created in 1992, is a federal drug pricing program that requires drug manufacturers to sell outpatient drugs at a discounted price to eligible safety-net organizations. Covered entities include Federally Qualified Health Centers such as RCC. The goal is to enable these health care facilities to utilize federal resources to serve more patients, provide more services, and lower outpatient drug costs for low-income patients.

As noted in the NYS Senate Bill S1913, “established by Congress to support providers serving vulnerable populations, the 340B program mandates drug manufacturers to provide discounts on outpatient drugs to clinics, hospitals, and health systems catering to low-income, rural, and medically underserved patients. By leveraging these discounts, safety-net providers can extend their resources to reach more eligible patients and offer comprehensive services.”³

Ryan Chelsea-Clinton and the 340B Program

The federal 340B Drug Pricing Program allows safety-net providers, including Community Health Centers (CHCs) such as RCC, known as covered entities, to purchase pharmaceutical drugs at discounted rates. CHCs rely on 340B to support and expand essential services that meet their communities’ needs. These services include subsidizing medications for the uninsured and underinsured, expanding access to dental and behavioral healthcare, establishing school-based health centers, and providing support for housing, transportation, and food assistance. CHCs are mandated to reinvest 340B savings into patient care and do so by expanding access, strengthening services, and providing discounts.

The 340B program protects and ensures that safety-net providers, such as RCC, have the resources to provide affordable medications and services to patients in need. Further, Senate Bill S1913 and Assembly Bill A6222 protects CHC patients to obtain discounted medications from their preferred pharmacy, including contract pharmacies to address individuals with transportation barriers. In addition, the Bills prevent Pharmacy Benefit Managers (PBMs) and for-profit entities from using discriminatory practices that prevent patient access and choice to medication.

How Senate Bill S1913 and Assembly Bill A6222 Assist and Support Ryan Chelsea-Clinton and Other Safety-Net Facilities

According to Senate Bill S1913, “this bill aims to prohibit such discriminatory practices and ensure that the savings from the 340B program remain available to safety-net health-care providers in New York State. By safeguarding the integrity of the 340B program, this legislation preserves vital resources for healthcare providers serving vulnerable populations, ultimately promoting equitable access to essential healthcare services across the state. The bill establishes enforcement mechanisms, including civil monetary penalties for violations, to uphold these protections and maintain the integrity of the 340B program in New York State.”

³ [The New York State Senate Bill S1913, 2025-2026 Legislative Session](#)

Alongside Assembly Bill A6222, these bills would prohibit denying or conditioning access to drugs based on 340B participation or imposing discriminatory reimbursement terms. Moreover, these Bills would provide covered entities, such as RCC, stronger legal protections against restrictions. This in turn would help make sure that patients have access to 340B drugs at lower costs and safety-net facilities have desperately needed funds to provide vital health care services.

NYS Senate Bill S1913 on February 4, 2025, was voted on in the Health Committee with a vote of 10 yea, 4 yea with reservations, and 1 nay, and as of that date was reported and committed to the Finance Committee. The corresponding NYS Assembly Bill A6222 was referred to the Health Committee on February 27, 2025.

Conclusion

MCB4 supports Senate Bill S1913 and Assembly Bill A6222 to:

- Ensure safety-net providers can continue to supply medications and receive discounted medications.
- Prevent PBMs and other for-profit entities from using discriminatory practices
- Ensure funds from the program go back into community health centers to care for the community.

We urge you and your colleagues to advance and pass Senate Bill S1913 and Assembly Bill A6222 to support safety-net facilities such as RCC that provide essential health services to vulnerable populations in our communities and to aid the patients that benefit from the 340B program.

RCC provides critical health care for our constituents. MCB4 recognizes the importance of the affordable and accessible health services that RCC brings to the community at large and the passage of NYS Senate Bill S1913 and Assembly Bill A6222 will protect and preserve these services.

Sincerely,



Jessica Chait
Chair
Manhattan Community Board 4



Joe Restuccia
Co-Chair
Housing, Health,
And Human Services
Committee

cc: Hon. Linda B. Rosenthal, NYS Assembly Member
Hon. Tony Simone, NYS Assembly Member
Hon. Brad Hoylman-Sigal, NYS Senate Member
Hon. Eric Adams, NYC Mayor
Hon. Mark Levine, Manhattan Borough President
Hon. Erik Bottcher, NYC Council Member
Hon. Gale Brewer, NYC Council Member
Sarina Jean-Louis, MBA, MPH, Executive Director, Ryan Chelsea-Clinton